|
R&D Leaders' Forum
Dr Douglas Throckmorton, Deputy Director, CDER, The Food and Drug Administration
Dr Keith James, Vice President, La Jolla Research Site Head, Pfizer Global R&D
Mahdi B. Fawzi, PhD, Executive Vice President, Preclinical Development, Wyeth Research
Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence (NICE)
Dr Mervyn J. Turner, Senior Vice President, Worldwide Licensing & External Research, Merck Research Laboratories, Merck & Co, Inc
Professor Jackie Hunter, Senior Vice President, Science Environment Development, GlaxoSmithKline
Robert J. Spiegel, MD, FACP, Senior Vice President & Chief Medical Officer, Schering-Plough Research Institute
Warwick S. Bedwell, Vice President & Global Head of Business Development, US, Hoffmann-La Roche Inc.
Dr Jean R. Slutsky, Director, Center for Outcomes & Evidence, Agency for Healthcare Research & Quality (AHRQ)
Dr David Boyko, Senior Vice President, Global Medical Affairs & Pharmacovigilance, Bristol-Myers Squibb
Dr Hartmut Ehrlich, Vice President, Global R&D, Baxter BioScience
Barbara Ryan, Managing Director, Deutsche Bank Securities, Inc
Dr Vanessa King, Head of Strategy & Operations, Novartis Institutes for BioMedical Research
Stuart T. Henderson, Americas Life Sciences Pharma R&D Leader, IBM Global Business Services
Dr Diana Galer, Vice President, Strategic Management Group, Pfizer Global R&D
Dr Wolfgang Wein, Senior Executive Vice President, Global Business Unit Oncology, Merck Serono
Karl E. Burgin, PhD, Project Leader, CODESTA Project (Coordinated Development Strategy for Asia), F. Hoffmann-La Roche AG
Dr Charles T. Gombar, Vice President, R&D Strategy & Business Improvement, Wyeth Research
John B. Edwards, President, Adnexus Therapeutics, Inc
Dr Christine J. Cioffe, Vice President, Strategic & Enterprise-wide Portfolio Management, Merck & Co, Inc
Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association
Dr Neil Weir, Senior Vice President, Research, UCB Celltech
Dr David R. Webb, Vice President, Research, Celgene Corporation
Nadine Cohen, Senior Vice President, Global Regulatory Affairs, Biogen Idec
Dr Dianne C. Kikta, Vice President, Global Clinical Strategic Resourcing, Wyeth Research
Dr William D. Matthews, Vice President, R&D Management Operations, Centocor R&D, Inc
David Brickwood, PhD, Vice President, International Government Affairs – Europe, Johnson & Johnson
Professor Pekka Kurki, Head of Licensing Department, National Agency for Medicines, Finland & Former Chair of the CHMP Biosimilar Working Party
John Larus, Chief Operating Officer, Fulcrum Pharma Developments, Inc
Dr Thorir Bjornsson, Vice President, Early Development & Clinical Pharmacology, Wyeth Research
Robert Baltera Jr, CEO, Amira Pharmaceuticals
Christine Carberry, Vice President, Program & Alliance Management, Biogen Idec
Dr Robert Booth, Operating Partner, TPG Ventures & Executive Chairman, ViroBay, Inc
Sanjeev Saxena, Chairman & CEO, Actis Biologics, India
Stephen Worland, PhD, President & Chief Executive Officer, Anadys Pharmaceuticals, Inc
Ian Sanderson, Managing Director & Senior Research Analyst, Cowen & Company, LLC
Patrick A. Baeuerle, PhD, Professor for Immunology, Senior Vice President, Chief Scientific Officer, Micromet, Inc
Dr Michelle Kramer, Senior Director, Johnson & Johnson Pharmaceutical R&D
Michael Hui, CEO, ShangPharma
Dr Peter L. Myers, Chief Executive Officer & Chairman of the Board, Lead Therapeutics
Neil M. Kurtz, MD, President & CEO, TorreyPines Therapeutics, Inc
Dr Lijun Sun, Vice President, Chemistry, Synta Pharmaceuticals
William F. Haddad, Chairman & CEO, BioGenerics, Inc
Robert H. Tidwell, Senior Vice President, Corporate Development, Cell Genesys
Ann L. Wang, Vice President, Clinical Operations/Data Management, Human Genome Sciences, Inc
Leyna Mulholland, PhD, Director, Global Regulatory Affairs, Pharma Development Regulatory (PDRA) - Japan Liaison, F. Hoffmann-La Roche Ltd
Dr Conor O'Dea, General Manager, Genemedix
Dr L. Christian Clauss, Director of New Product Development, RA Global Biologics, Baxter International
Mike McCully, Director & Senior Analyst, Recombinant Capital, Inc
Dr Brenda L. Gaydos, Research Advisor, Eli Lilly and Company
|
Oncology Leaders' Forum
Dr David Parkinson, President & CEO, Nodality, Inc
Professor Sir Michael Rawlins, Chairman, National Institute for Clinical Excellence
Kerry L. Blanchard, PhD, MD, Chief Operating Officer - Discovery Research, Eli Lilly & Company
Robert Glassman, MD, Managing Director, Healthcare Investment Banking, Merrill Lynch & Co
Stafford O'Kelly, President, Abbott Molecular Inc
Dr Neil W. Gibson, Vice President, Oncology Research Therapeutic Area Head, Pfizer La Jolla
Dr Wolfgang Wein, Senior Executive Vice President, Global Business Unit Oncology, Merck Serono
Dr Jean R. Slutsky, Director, Center for Outcomes & Evidence, Agency for Healthcare Research & Quality (AHRQ)
Giulio F. Draetta, MD, PhD, Vice President, Worldwide Basic Research Oncology Franchise Head, Merck Research Laboratories
Dr Jeffrey Hanke, Vice President, Cancer Research, R&D Boston, AstraZeneca
Donald P. Rosen, MD, Founder & Chief Strategy Officer, RadPharm Inc
Dr Jerry Lanchbury, Executive Vice President, Research, Myriad Genetics, Inc
Dr David J. Brickwood PhD, Vice President, International Government Affairs - Europe, Johnson & Johnson
Stuart T. Henderson, Americas Life Sciences Pharma R&D Leader, IBM Global Business Services
Dr Rajesh Shrotriya, CEO, Spectrum Pharmaceuticals
Dr Charles T. Gombar, Vice President, R&D Strategy & Business Improvement, Wyeth Research
Professor Eva Skovlund, Senior Adviser, Norwegian Medicines Agency
Dr Roy Baynes, Vice President, Clinical Development, Therapeutic Area Head, Oncology Supportive Care, Amgen, Inc
Naomi Aronson, PhD, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association
Christopher Bowden, MD, Senior Group Medical Director, BioOncology Development- Avastin, Genentech Inc
M. J. Finley Austin, PhD, US Head, External Research & Innovation Environment, Hoffmann-La Roche Inc
Alison Ayers, Worldwide Commercial Head for Oncology, Pfizer
Jerald S. Schindler, DrPH, Vice President, Biostatistics & Research Decision Sciences, Late Stage Clinical Development Statistics, Merck Research Laboratories
Dr Robert M. Miller FRCS MBBS FFPM, Chief Medical Officer, Fulcrum Pharma plc
Professor Donald Berry, Chairman, Department of Biostatistics & Frank T. McGraw Memorial Chair of Cancer Research, MD Anderson Cancer Center
Dr David D. Chang, Vice President, Global Clinical Development, Oncology Therapeutics, Amgen
Dr Richard D. Hockett, Senior Clinical Research Physician, Group Leader for Genomic Medicine, Department of Diagnostics & Experimental Medicine, Eli Lilly and Company
Dr J. Carl Barrett, Global Head of Oncology Biomarkers and Imaging, Novartis Institutes of BioMedical Research, Inc
Dr Nicholas C. Dracopoli, Vice President, Biomarkers, Centocor Research & Development, Inc.
Dr Gary Acton, Chief Medical Officer, Antisoma
Michael Pollock, Vice President, Global Health Economics, Biogen Idec, Inc
Jonathan M. Yingling, PhD, Chief Scientific Officer, Angiogenesis & Tumor Microenvironment Biology, Eli Lilly and Company
Dr Pearl S. Huang, Vice President, Franchise Integrator, Oncology, Merck & Co
Gary Palmer, MD, JD, MBA, MPH, Vice President, Medical Affairs, Genomic Health, Inc
Dr Jeffrey L. Evelhoch, Executive Director, Medical Sciences, Imaging, Amgen
Jens Oliver Funk, MD, Head, Oncology Therapeutic Area, Merck Serono Research, Merck KGaA
Dr Gerd Maass, Head of Research & Development, Roche Applied Science, Roche Diagnostics GmbH
W. Neil Palmer, Vice President, Pricing & Reimbursement, RTI Health Solutions
Dr Howard Fingert, Senior Director & Clinical Lead, Signal Transduction Development Program, Pfizer Oncology
Eric Perlman, MD, Director, Molecular Imaging & Biomarkers, RadPharm Inc
Richard Simon, DSc, Chief, Biometric Research Branch, National Cancer Institute
Dr Jeremy Barton, Senior Director, Medical Research, Biogen Idec
Dr Julie Lisano, Senior Medical Director, Abraxis Oncology
Markus Warmuth, MD, Executive Director, Oncology Drug Discovery, Novartis Institutes for BioMedical Research
Renee Bailey Iacona, PhD, MPH, Director- Statistical Science, Oncology, AstraZeneca Pharmaceuticals
Julie D. Maltzman, MD, Director, Oncology Medicine Development Center, GlaxoSmithKline
Sharon Isonaka, MD, MS, Executive Director, Global Pricing & Payer Planning, Amgen
Gary E. Fishbein, MD, MPH, Senior Medical Director, Oncology, PharmaNet Development Group, Inc
Athena M. Countouriotis, MD, Director, Oncology Clinical Development, Pfizer La Jolla
Dr Susanta K. Sarkar, Director, Clinical Imaging, Oncology Medicine Development Center, GlaxoSmithKline
|
